Tag: jeffrey cohen

19-NEU-156-Cohen-profile-as-ACTRIMS-Chair-CQD_Hero650x450
February 27, 2019/News & Insights

New Chair Aims to Keep ACTRIMS Up to Pace with Dynamism of the Multiple Sclerosis Field

Dr. Jeffrey Cohen on ACTRIMS Forum 2019 and trends in the subspecialty

18-NEU-820-Generic-MS-Drugs-650×450
April 23, 2018/Insight & Perspectives

Generics and Biosimilars in Multiple Sclerosis: Navigating a New Therapy Landscape

What neurologists need to know about this emerging development

650×450-Cohen
December 29, 2017/News & Insights

Updated McDonald Criteria for MS Diagnosis Are Out: Q&A with the Revision Co-Chair

Dr. Jeffrey Cohen says changes streamline diagnosis and extend scope to new populations

17-NEU-716-Cohen-Stem-Cell-650×450
April 25, 2017/Insight & Perspectives

Stem Cell Therapies for Neurological Diseases: The Devil’s in the Details

Dr. Jeffrey Cohen on the challenges that temper the promise

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

17-NEU-715-Cohen-Radiance-650×450
April 25, 2017/Research

RADIANCE Extension: Ozanimod’s Favorable Effects in Relapsing MS Endure to Two Years

Continued benefit on MRI activity without first-dose cardiac effects

650×450-Coen
January 19, 2016/Insight & Perspectives

A Long-Awaited Gateway to Generics for Multiple Sclerosis

Q&A with lead author of the GATE trial

690×380-Cohen-Gate-Study
March 26, 2015/Advancing Patient Care

Results of GATE Trial Pave Way for More-Affordable MS Therapy

Generic glatiramer acetate proves equivalent to Copaxone®

690×380-Cohen-Stem-Cells
March 12, 2015/Research

Stem Cell Therapy for MS Gets Green Light in First U.S. Clinical Trial

No safety issues or signs of MS activation

BackPage 1 of 1Next
Advertisement
Ad